Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
News-Outstanding Corporate Governance Evaluation Results for the Microbio Group Microbio and Oneness Rank among Top 5% in the Corporate Governance Evaluation for Four Consecutive years; Diamond Biofund Enters Top 5% on Its First Evaluation
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2024
2024
Date
Title
2024-06-21
Oneness announces the information about the investor’s conference of 2024 Q2.
>
2024-06-14
Oneness announces on behalf of major subsidiary Cotton Field Organic Farm Inc. for the election of the Chairperson.
>
2024-06-14
Oneness announces on behalf of major subsidiary Cotton Field Organic Farm Inc. for 2024 Shareholders’Meeting approved removal of the noncompete clause for directors.
>
2024-06-14
Oneness announces on behalf of major subsidiary Cotton Field Organic Farm Inc. for election of Directors and Supervisor at the 2024 Annual Shareholders’Meeting.
>
2024-06-14
Oneness announces on behalf of major subsidiary Cotton Field Organic Farm Inc. for the important resolutions of the 2024 Annual General Shareholders’ Meeting
>
2024-05-23
U.S. FDA notified Oneness today that Bonvadis for partial thickness wounds, closed post-surgical wounds, and burns (1st and superficial 2nd degrees) is 510(k) cleared.
>
2024-05-21
2024 Shareholders’ Regular Meeting of the Company approved removal of the noncompete clause for newly directors.
>
2024-05-21
Oneness announce re-election of all directors in the 2024 Annual General Shareholders’ Meeting.
>
2024-05-21
Oneness announce the important resolutions of the 2024 Annual General Shareholders’ Meeting
>
2024-05-21
Oneness announce the newly-elected member of the Compensation Committee
>
2024-05-21
Oneness announce that the Company’s Board of Directors elected the Chairperson.
>
2024-05-21
Oneness announce the newly-elected member of the Audit Committee
>
2024-05-17
According to U.S. FDA’s suggestion, the company agrees to withdraw the 510(k) for Bonvadis chronic wound and resubmit after the supplementing animal study data.
>
2024-05-13
The Company’s 2024Q1 consolidated financial statements have been approved by the Board of Directors
>
2024-05-13
The board of directors of the Company approved removal of the noncompete clause for managers.
>
« Previous
1
2
3
4
5
Next »